



For immediate release

Theratechnologies appoints former Montreal Stock Exchange President and CEO to its Board of Directors

Montreal, February 8, 2006 – Mr. A. Jean de Grandpré, Chairman of the Board of Directors of Theratechnologies, is pleased to announce the appointment of Mr. Gérald A. Lacoste as a director of the Company.

Mr. Lacoste is a lawyer with extensive experience in the fields of securities regulation, financing and corporate governance. He was previously President of the Quebec Securities Commission (now known as the Autorité des marchés financiers) and was also President and CEO of the Montreal Stock Exchange. During his career, Mr. Lacoste acted as legal counsel to the Standing Senate Committee on Banking, Trade and Commerce, he chaired the Quebec Advisory Committee on Financial Institutions, and was a member of the working group responsible for reviewing the capitalization of life insurance companies in Quebec. Mr. Lacoste is currently a corporate director, actively involved in the biotechnology industry, and is a member of the North American Free Trade Agreement (NAFTA) arbitration panel.

"We are very proud to welcome Mr. Lacoste to our Board of Directors. His impressive track record in business, law and corporate governance will be a significant asset to Theratechnologies", Mr. de Grandpré stated. "With his diverse experience, Mr. Lacoste brings complementary strengths to the Board and his contribution is certain to benefit the Company greatly", he added.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets where it can retain full or partial commercial rights for its products. Its most advanced program is TH9507, now in Phase 3 clinical trials for a serious metabolic syndrome known as HIV-associated lipodystrophy. The Company also has other promising projects at earlier stages of development.

###

Contact:

Yves Rosconi
President and Chief Executive Officer
514-336-4804, Ext. 221
yrosconi@theratech.com